StockNews.com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)

Investment analysts at StockNews.com initiated coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Eiger BioPharmaceuticals Price Performance

The stock has a market capitalization of $2.55 million, a P/E ratio of -0.03 and a beta of 1.83. The firm’s 50-day moving average price is $4.94 and its 200 day moving average price is $7.08. Eiger BioPharmaceuticals has a one year low of $1.10 and a one year high of $43.35.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.